In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.04 below Altimmune Inc average.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Altimmune Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 30, from total ranking in the first quarter 2026 at 77.

Explain Quick Ratio?
How much Cash & cash equivalents ALT�s has?
What are ALT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	1368.98 %	42.06 %	194.69 %	324.01 %	-68.34 %
Y / Y Cash & cash equivalent Change	-65.59 %	121.28 %	107.33 %	51.22 %	11.03 %
Quick Ratio MRQ	5.04	216.69	100.65	43.88	215.16
ALT's Total Ranking	# 30	# 77	# 135	# 39	# 57
Seq. Current Liabilities Change	717.06 %	-43.69 %	-43.44 %	464.51 %	-20.98 %
Seq. Cash & cash equivalent Change	-81 %	21.24 %	29.74 %	15.11 %	22.21 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 186
Healthcare Sector	# 303
Overall Market	# 808

Quick Ratio Statistics
High	Average	Low
32778.67	819.33	0.88
(Sep 30 2021)		(Mar 31 2018)

Financial Statements
Altimmune Inc 's Current Liabilities	$ 13 Millions	Visit ALT's Balance sheet
Altimmune Inc 's Cash & cash equivalent	$ 63 Millions	Visit ALT's Balance sheet
Source of ALT's Sales		Visit ALT's Sales by Geography

Cumulative Altimmune Inc 's Quick Ratio

ALT's Quick Ratio for the trailling 12 Months

ALT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	441.1 %	70.14 %	11.13 %	-26.13 %	-67.55 %
Y / Y Cash & cash equivalent TTM Growth	45.44 %	70.46 %	32.18 %	-1.25 %	-11.86 %
Quick Ratio TTM	40.77	100.88	86.48	88.27	151.7
Total Ranking TTM	# 173	# 228	# 120	# 125	# 307
Seq. Current Liabilities TTM Growth	117.65 %	4.79 %	23.45 %	92.17 %	-31.56 %
Seq. Cash & cash equivalent TTM Growth	-12.02 %	22.24 %	20.95 %	11.82 %	3.11 %

Quick ratio ranking by company, industry and sector >> Back to ALT Financial Strength Comparisons >> Go to Compare ALT Quick Ratio to its Competitors

News about Altimmune inc Quick Ratio

Advancements in Non-Alcoholic Steatohepatitis Management Altimmunes Pemvidutide Phase 2b Results and Financial Stand...

Recent developments in the treatment of non-alcoholic steatohepatitis (NASH) highlight the increasing potential of emerging therapies. Notably, Altimmune Inc. is poised to present compelling findings from its Phase 2b clinical trial of Pemvidutide, a novel therapeutic candidate for managing moderate to severe alcohol-related liver disease. This presentation will take place during the esteemed AASLD The Liver Meeting 2025, marked by a late-breaking oral podium presentation and a supporting late-breaking poster, both of which will illuminate the efficacy and safety outcomes observed over 24 weeks of treatment. Furthermore, this article delves into Altimmune s recent financial advancements, underscoring the company s robust fiscal health amidst its innovative pipeline.Non-alcoholic steatohepatitis (NASH) represents a significant global health concern, characterized by the accumulation of fat in the liver, leading to inflammation and potential progression to cirrhosis and hepatocellular carcinoma. The critical need for effective interventions in this domain has propelled research into new therapeutic agents. Altimmune Inc. s Pemvidutide emerges as a promising candidate, demonstrating the potential to modulate liver fat and improve metabolic health.

Investor Alert Legal Challenges Loom for Altimmune and SelectQuote Amidst Mixed Financial Signals

In a noteworthy development for investors, Bragar Eagel and Squire, P.C., a prominent shareholder rights law firm, has issued a reminder regarding ongoing class action lawsuits against Altimmune, Inc. (NASDAQ: ALT) and SelectQuote, Inc. (NYSE: SLQT). Stockholders of these companies are encouraged to act swiftly, as the deadlines for petitioning the court to become lead plaintiffs are approaching.As competitive dynamics continue to evolve in the biotech and insurance markets, Altimmune s recent financial performance raises eyebrows. In Q2 2025, the company reported a revenue stagnation year-over-year, marking a 0% change, while many of its competitors enjoyed a robust growth rate of 4.88%. This divergence has prompted scrutiny from investors and industry analysts alike, particularly as Altimmune struggled to translate income growth into profitability.

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $12.50 millions, cumulative Quick Ratio decreased to 40.77 above the ALT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Altimmune Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2843.

Explain Quick Ratio?
How much Cash & cash equivalents ALT�s has?
What are ALT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 422
Healthcare Sector	# 858
Within the Market	# 30

trailing twelve months Quick Ratio Statistics
High	Average	Low
15.67	6.73	1.04
(Jun 30 2021)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Pmv Pharmaceuticals Inc	13.85	$ 146.393 Millions	$ 10.568 Millions
Generate Biomedicines Inc	13.76	$ 779.456 Millions	$ 56.636 Millions
First Tracks Biotherapeutics Inc	13.50	$ 168.018 Millions	$ 12.447 Millions
Arrivent Biopharma inc	13.41	$ 373.401 Millions	$ 27.844 Millions
Cogent Biosciences Inc	13.36	$ 792.300 Millions	$ 59.296 Millions
Aprea Therapeutics Inc	13.33	$ 41.233 Millions	$ 3.092 Millions
Polaryx Therapeutics Inc	13.22	$ 11.542 Millions	$ 0.873 Millions
Monopar Therapeutics Inc	13.14	$ 52.758 Millions	$ 4.016 Millions
Lexicon Pharmaceuticals Inc	12.96	$ 190.610 Millions	$ 14.706 Millions
Korro Bio Inc	12.89	$ 162.805 Millions	$ 12.628 Millions
Atea Pharmaceuticals Inc	12.89	$ 362.382 Millions	$ 28.124 Millions
Oric Pharmaceuticals Inc	12.76	$ 264.761 Millions	$ 20.756 Millions
Diamedica Therapeutics Inc	12.42	$ 81.875 Millions	$ 6.594 Millions
Vtv Therapeutics Inc	12.35	$ 86.643 Millions	$ 7.017 Millions
Theravance Biopharma inc	12.30	$ 378.546 Millions	$ 30.766 Millions
Coya Therapeutics Inc	12.29	$ 43.181 Millions	$ 3.512 Millions
Bridgebio Oncology Therapeutics Inc	12.28	$ 634.167 Millions	$ 51.634 Millions
Ocular Therapeutix Inc	12.17	$ 598.641 Millions	$ 49.174 Millions
Wave Life Sciences Ltd	12.07	$ 613.194 Millions	$ 50.815 Millions
Amylyx Pharmaceuticals Inc	11.86	$ 250.760 Millions	$ 21.150 Millions
Moonlake Immunotherapeutics	11.83	$ 537.000 Millions	$ 45.392 Millions
Eledon Pharmaceuticals Inc	11.77	$ 170.753 Millions	$ 14.503 Millions
Tyra Biosciences Inc	11.76	$ 354.060 Millions	$ 30.106 Millions
Opus Genetics Inc	11.69	$ 88.912 Millions	$ 7.605 Millions
Aardvark Therapeutics Inc	11.57	$ 73.921 Millions	$ 6.387 Millions
Dyne Therapeutics Inc	11.51	$ 898.475 Millions	$ 78.029 Millions
Evommune Inc	11.50	$ 201.014 Millions	$ 17.487 Millions
Bicara Therapeutics Inc	11.44	$ 497.259 Millions	$ 43.475 Millions
Lipocine Inc	11.25	$ 23.267 Millions	$ 2.068 Millions
Xenon Pharmaceuticals Inc	10.85	$ 930.686 Millions	$ 85.795 Millions

Date modified: 2026-09-12T06:15:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.